ButaTabs D

Manufacturer: Butler

Phenylbutazone 100mg Tablets

An effective treatment for painful inflammatory conditions musculoskeletal system in dogs, including fractures, arthritis, and painful injuries to the limbs and joints.

Non-hormonal anti-inflammatory agent, unrelated to the corticosteroid anti-inflammatory agents.

Description

Phenylbutazone is the generic name of the drug known chemically as 4-butyl 1,2-diphenyl-3,5-pyrazolidinedione.

Phenylbutazone is a white crystalline solid, slightly soluble in water, and soluble in some organic solvents. It does not have an odor, but has a slightly bitter taste.

Background Pharmacology

Phenylbutazone is a nonhormonal anti-inflammatory agent. It is unrelated to the corticosteroid anti-inflammatory agents. The anti-inflammatory activity of phenylbutazone has been shown in lower animals (1) and in man (2). The greatest amount of data on efficacy is in man (3-6). Studies in dogs have reported useful anti-inflammatory activity in the treatment of painful conditions of the musculoskeletal system (1-7). These conditions include painful fractures, arthritis, and painful injuries to the limbs and joints.

ButaTabs D Indications

Phenylbutazone is used for the treatment of inflammatory conditions of the musculoskeletal system in dogs.

Contraindications

Phenylbutazone should not be administered to patients with serious hepatic, renal or cardiac pathology, or those with a history of blood dyscrasia.

Hazards And Precautions

1. Use with caution in patients with a history of drug allergies.

2. Stop the medication at the first sign of gastrointestinal upset, jaundice or blood dyscrasia. Cases of agranulocytosis associated with phenylbutazone have occurred in man. Only one case has been reported in veterinary medicine in a dog on high level, long-term therapy.

3. To guard against this possibility, conduct routine blood counts at not more than seven-day intervals during the early course of therapy. Any significant fall in the total white count, relative decrease in granuloctyes or black or tarry stool should be a sign for immediate cessation of therapy and the institution of appropriate treatment.

4. When treating inflammatory conditions associated with infections, anti-infective therapy is required.

5. The response to phenylbutazone therapy occurs within 24 hours. If a significant clinical response is not evident after five days of therapy, re-evaluate the diagnosis and therapeutic regimen.

Dosage (dogs)

Orally: 20 mg per pound body weight (100 mg/5 lbs) daily in three divided doses, but not to exceed 800 mg daily, regardless of body weight.

Administration

1. Use a high dose for the first 48 hours, then reduce it gradually to a maintenance dose. Maintain the lowest dose capable of producing the desired clinical response.

2. In many cases, the tablets may be crushed and given with food. Reduce the dose as symptoms regress. In some cases, treatment may be given only when symptoms appear, without need for continuous medications. If a long term therapy is planned, oral administration is suggested.

3. In animals, phenylbutazone is mostly metabolized within eight (8) hours. It is recommended that one-third (1/3) of the daily dose be administered at 8-hour intervals.

4. Many chronic conditions will respond to phenylbutazone therapy but discontinuance of the treatment may result in the recurrence of symptoms.

ButaTabs D Caution

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

How Supplied

Bottles of 1000 tablets, each tablet containing 100 mg of phenylbutazone.

References

1. Lieberman, L.L., Jour. Amer. Vet. Assoc. 125; 128, 1954

2. Kuzell, W.C., Schaffarzick, R.W., Naugler, W.F., and Mankle, E.A.: A.M.A. Arch. Int. Med. 92:646, 1953.

3. Payne, R.W., Sheltlar, M.R., Farr, C., Hellbaum, A.A. and Ishmael, W.K.T., J. Lab. Clin. Med. 45:331, 1955.

4. Fleming, J., and Will, G.: Ann. Rheumat. Dis. 12:95, 1953.

5. Denko, C.W., and Ruml, D.: Amer. Practit. 6:1865, 1955.

6. Yourish, N., Paton, B., Brodie, B.B., and Burns, J.J.: A.M.A. Arch. Ophth. 53:264, 1955.

7. Joshua, J.O.: Vet. Rec. 68:60 (Jan. 21), 1956.

Nac No.

10822500